Q-Line Biotech Shares Rally on Nasdaq-SME Listing, Trades at 32% Premium

Q-Line Biotech Shares Make Strong Debut on NSE SME, Defying Cautious Market Sentiment

Q-Line Biotech shares made a strong debut on the NSE SME on Friday, 29 May, extending gains further despite cautious market sentiment. The company's share price opened at ₹452 on the NSE SME, a nearly 32% increase from its issue price of ₹343. The share price rose further to ₹460 during the session, representing a gain of over 34% from its issue price.

As of 11:50 am, the SME stock was trading at ₹447.15, a 30.36% increase from its issue price. This healthy listing of the stock follows Q-Line Biotech's strong subscription, with the IPO receiving nearly 72 times subscription. The Q-Line Biotech IPO was an entirely fresh issue of 62,53,200 shares, priced at ₹343, aiming to raise nearly ₹214.48 crore. The funds raised will be utilized for meeting working capital requirements, repayment of certain borrowing, in part or in full, and general corporate purposes.

Q-Line Biotech is engaged in the business of developing, manufacturing, and marketing a diverse range of reagents, including kits and POC devices, and consumables and manufacturing, importing, distribution, and supply of diagnostic equipment for different diagnostic healthcare needs. The company has been supplying diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013, with its core segments of operations including clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and others (POC devices and rapids).

Read also: SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

In the first nine months of FY26, Q-Line Biotech reported revenue from operations of ₹232.42 crore, while its profit for the period was ₹38.69 crore.